BB
The startup develops targeted antibody therapies specifically for ophthalmic diseases by utilizing antibody discovery technologies focused on genetically validated ophthalmology targets. This approach enables the delivery of effective treatments for patients suffering from various eye conditions.
Updated 2 months ago
Funding
$9.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops targeted antibody therapies specifically for ophthalmic diseases by utilizing antibody discovery technologies focused on genetically validated ophthalmology targets. This approach enables the delivery of effective treatments for patients suffering from various eye conditions.